Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.85 |
| ▸ | KIT | P10721 | 9/20 | 0.85 |
| ▸ | ABL2 | P42684 | 6/20 | 0.85 |
| ▸ | BCR | P11274 | 5/20 | 0.85 |
| ▸ | LCK | P06239 | 3/20 | 0.85 |
| ▸ | CSF1R | P07333 | 3/20 | 0.85 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.85 |
| ▸ | EGFR | P00533 | 2/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.85 |
| ▸ | FYN | P06241 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 2/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.85 |
| ▸ | FGR | P09769 | 2/20 | 0.85 |
| ▸ | SRC | P12931 | 2/20 | 0.85 |
| ▸ | BRAF | P15056 | 2/20 | 0.85 |
| ▸ | NQO2 | P16083 | 2/20 | 0.85 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.85 |
| ▸ | FRK | P42685 | 2/20 | 0.85 |
| ▸ | BLK | P51451 | 2/20 | 0.85 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715899 | 0.94 | KIT (0.85) | ABL1KITABL2BCRLCK | |
| SCHEMBL5197795 | 0.93 | ABL1 (0.78) | ABL1KITABL2BCRLCK | |
| SCHEMBL715883 | 0.93 | ABL1 (0.79) | ABL1KITABL2BCRLCK | |
| Masitinib SCHEMBL29353195 | 0.92 | ABL1 (1.00) | ABL1KITABL2BCRLCK | |
| Masitinib SCHEMBL29355443 | 0.92 | ABL1 (1.00) | ABL1KITABL2BCRLCK | |
| Masitinib SCHEMBL717239 | 0.92 | ABL1 (1.00) | ABL1KITABL2BCRLCK | |
| SCHEMBL717524 | 0.92 | ABL1 (0.78) | ABL1KITABL2BCRLCK | |
| SCHEMBL715885 | 0.92 | ABL1 (0.80) | ABL1KITABL2BCRLCK | |
| SCHEMBL717867 | 0.91 | ABL1 (0.76) | ABL1KITABL2BCRLCK | |
| SCHEMBL715933 | 0.90 | ABL1 (0.78) | ABL1KITABL2BCRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | AB SCIENCE | 2008-10-16 | — | — | US | claimed |
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | claimed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | claimed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | claimed |
| US-20050239852-A1 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2005-10-27 | — | — | US | claimed |
| US-20040110810-A1 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE | 2004-06-10 | — | — | US | claimed |
| US-20160022671-A1 | TREATMENT OF MASTOCYTOSIS WITH MASITINIB | AB SCIENCE (FR) | 2016-01-28 | — | — | US | disclosed |
| US-20160022671-A1 | TREATMENT OF MASTOCYTOSIS WITH MASITINIB | AB SCIENCE (FR) | 2016-01-28 | — | — | US | disclosed |
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8835435-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2014-09-16 | — | — | US | disclosed |
| US-8835435-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | AB SCIENCE (FR) | 2014-03-27 | — | — | US | disclosed |
| WO-2005102318-A1 | USE OF C-KIT INHIBITORS FOR TREATING HIV RELATED DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239852-A1 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2005-10-27 | — | — | US | disclosed |
| EP-1525200-A1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB Science (FR) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005016323-A2 | USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES | AB SCIENCE (FR) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004096225-A2 | USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA | AB SCIENCE (FR) | 2004-11-11 | — | — | WO | disclosed |
| US-20040110810-A1 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE | 2004-06-10 | — | — | US | disclosed |
| WO-2004014903-A1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022671-A1 | TREATMENT OF MASTOCYTOSIS WITH MASITINIB | MAST3, MAST1, KIT | ABL1 10/4885KIT 3/4885ABL2 107/4885 |
| US-20040110810-A1 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | KIT, MAP3K2, CMA1 | ABL1 251/4885KIT 1/4885ABL2 313/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | ABL1 233/4885KIT 1/4885ABL2 131/4885 |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | KIT, CHUK, CKS1B | ABL1 22/4885KIT 1/4885ABL2 65/4885 |
| US-20050239852-A1 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | KIT, CHUK, MAP3K2 | ABL1 36/4885KIT 1/4885ABL2 90/4885 |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | KIT, MAP3K1, MAP3K6 | ABL1 176/4885KIT 1/4885ABL2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.